News By Tag
* Drug Formulation
* Formulation Development
* Clinical Trial Manifacturing
* More Tags...
News By Location
Follow on Google News
Xcelience Reduces Time to Phase I Studies by 17 Weeks Using API into Capsule Services
Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600/600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA).
By: Derek Hennecke
“Today’s molecule is under pressure” says Derek Hennecke, CEO and President. “We need to work smarter with clients to make the best choices, often with limited material. One of the best decisions we made was to put our money on Xcelodose ® (http://www.xcelience.com/
"Our defined API into Capsule program is a true differentiator, but not the only one” adds V.P. Randall H. Guthrie, “Xcelience combines decades of drug development experience, state-of-the-
Xcelience is also announcing a strategic expansion focused on areas of proven strength: low weight fills and potent compounds for API into capsule, continued expansion and growth of its formulation development team, implementation of UPLC analytical capability, investment in x-ray diffraction for preformulation activities, and blister packaging in support of client’s clinical supply needs. Development of the purpose-built Grace Street expansion continues as planned.
Xcelience LLC, is a contract research organization which has been providing formulation development (http://www.xcelience.com/
About Xcelience: Keep on top of new developments in Xcelience and throughout the drug development industry by following us on Twitter www.twitter.com/
# # #
Xcelience is the industry expert in formulation development. From analysis through formulation and manufacturing, our extensive background and impressive talents are becoming well known throughout the scientific world.